An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (FUTURE SUPER)
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Bevacizumab (Primary) ; Camrelizumab (Primary) ; Capecitabine (Primary) ; Everolimus (Primary) ; Famitinib (Primary) ; Paclitaxel (Primary) ; Pyrotinib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms FUTURE SUPER
Most Recent Events
- 08 Jan 2024 Primary endpoint has been met. (investigator-assessed progression-free survival for the pooled subtyping-based group versus the control group in the intention-to-treat population (all randomly assigned participants), as per published in the Lancet Oncology
- 08 Jan 2024 Results evaluating the efficacy and safety of subtyping-based therapy in the first-line treatment of triple-negative breast cancer, published in the Lancet Oncology
- 17 Dec 2023 Planned End Date changed from 15 Nov 2023 to 31 Dec 2024.